Coldstream Capital Management
LRMR icon

Coldstream Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Coldstream Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,334
Closed -$62.2K – 1239
2025
Q4 		$62.2K Sell
16,334
-1,199
-7% -$4.66K ﹤0.01% 1145
2025
Q3 		$56.6K Buy
+17,533
New +$65.7K ﹤0.01% 1203

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Coldstream Capital Management's LRMR Position: Q1 2026 in Review

Coldstream Capital Management sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 16,334 shares — an estimated $62.2K sold.

Coldstream Capital Management first reported a position in LRMR in Q3 2025 and held it in 2 quarters. The position peaked at $62.2K in Q4 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Coldstream Capital Management reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Coldstream Capital Management sold 16,334 Larimar Therapeutics shares in Q1 2026, an estimated $62.2K.
  • Coldstream Capital Management first reported a position in Larimar Therapeutics in Q3 2025 and held it in 2 quarters.
  • Coldstream Capital Management's Larimar Therapeutics position peaked at $62.2K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.